Icon Plc $ICLR Shares Bought by Fisher Funds Management LTD

Fisher Funds Management LTD grew its stake in shares of Icon Plc (NASDAQ:ICLR) by 19.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 513,102 shares of the medical research company’s stock after acquiring an additional 82,019 shares during the period. Icon comprises about 2.4% of Fisher Funds Management LTD’s portfolio, making the stock its 7th largest holding. Fisher Funds Management LTD’s holdings in Icon were worth $93,208,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of ICLR. Muhlenkamp & Co. Inc. acquired a new stake in Icon during the 3rd quarter valued at $12,857,000. Mitchell Capital Management Co. acquired a new stake in Icon during the 3rd quarter valued at $1,627,000. First National Bank of Omaha acquired a new stake in Icon during the 3rd quarter valued at $6,267,000. Tributary Capital Management LLC raised its stake in Icon by 84.5% during the 3rd quarter. Tributary Capital Management LLC now owns 11,752 shares of the medical research company’s stock valued at $2,057,000 after purchasing an additional 5,381 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Icon by 1.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock valued at $203,800,000 after purchasing an additional 11,335 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Trading Down 0.8%

NASDAQ ICLR opened at $115.58 on Friday. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $9.33 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 2.95 and a beta of 1.28. The firm’s fifty day simple moving average is $107.33 and its 200-day simple moving average is $154.34.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Leerink Partners reissued a “market perform” rating and set a $105.00 target price on shares of Icon in a research note on Thursday, February 12th. Barclays cut their target price on shares of Icon from $200.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Monday, March 9th. TD Cowen raised shares of Icon from a “hold” rating to a “buy” rating and cut their target price for the company from $183.00 to $120.00 in a research note on Wednesday, February 18th. Weiss Ratings downgraded shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Finally, Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Icon has a consensus rating of “Hold” and a consensus target price of $148.80.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.